CellSeed logo — Advancing regenerative medicine with innovative cell sheet t...

CellSeed

Advancing regenerative medicine with innovative cell sheet therapies for eyes, esophagus, heart, gums, and joints since 2001.

Founded 2001 Post Ipo Equity Total: $3.17B Health Care, Marketing

General Information

Company Name CellSeed
Founded Year 2001
Industries Health Care, Marketing
Funding Stage Post Ipo Equity
Social

Get notified when CellSeed moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About CellSeed

CellSeed is a regenerative medicine startup that has been advancing cell sheet therapies for various medical applications since 2001. With a focus on Japan and Europe, the company offers a range of innovative products including epithelial cell sheets for corneal and esophageal regeneration, cardiac patches for heart disease treatment, cell sheets for periodontal tissue regeneration, and cartilage sheets for osteoarthritis care. The company is based in Tokyo, Japan. In March 2014, CellSeed received a significant ¥509.33M post-IPO equity investment from Whiz Partners, indicating confidence in the company's potential within the regenerative medicine sector. This investment further solidified the company's position in the market and underscored its growth trajectory. With a strong track record and a steadfast commitment to innovation in regenerative medicine, CellSeed continues to be a compelling opportunity for potential investors seeking to tap into the evolving landscape of healthcare and medical technology.

Taxonomy: Regenerative Medicine, Cell Therapy, Japan, Europe, Epithelial Cell Sheets, Cardiac Patches, Periodontal Tissue Regeneration, Corneal Regeneration, Esophageal Regeneration, Heart Disease Treatment, Osteoarthritis Care, Innovation, Research and Development

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• 1
Investor
04 Mar 2014
Venture Round •••••• 3
Investor Investor
•••• ••••
16 Jan 2009
Venture Round •••••• 6
Investor Investor Investor Investor Investor
•••• ••••
02 Nov 2005
Venture Round •••••• - 30 Sep 2005

CellSeed Alternatives & Competitors

CellSeed vs

Curing blindness with regenerative cell therapies.

Seed
16 employees
Biotechnology, Health Care
CellSeed vs

Focused on pioneering advancements in regeneration technology since 2003, with roots in Tokyo, Japan

Series B
Care Economy, Health and Wellness
CellSeed vs
VascVersa Ltd
VascVersa Ltd United Kingdom

Restoring life where its needed most

Seed
6 employees
Health Care

FAQ About CellSeed

Advancing regenerative medicine with innovative cell sheet therapies for eyes, esophagus, heart, gums, and joints since 2001.
CellSeed was founded in 2001.
CellSeed operates in the following industries: Health Care, Marketing.
CellSeed has completed 4 funding rounds, raising a total of $3.17B. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to CellSeed include StemSight - Vision Unlimited, TWO CELLS Co.,Ltd, VascVersa Ltd, Celling Biosciences, Heart Regeneration Technologies GmbH, by Avenns Medical. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CellSeed and StemSight - Vision Unlimited are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors CellSeed and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy